NCT05248594: Real World Use of Emicizumab in Infants and Children Ages 0-3 Years With Hemophilia A |
|
|
| Recruiting | N/A | 50 | US | HEMLIBRA, Emicizumab-kxwh | Montefiore Medical Center, Genentech, Inc. | Hemophilia A | 08/25 | 08/25 | | |
| Recruiting | N/A | 3000 | US | | American Thrombosis and Hemostasis Network, Pfizer, Hemophilia of Georgia, Inc., Genentech, Inc., Hemab Therapeutics, CSL Behring, Sanofi, Novo Nordisk A/S | Hematologic Disorder, Bleeding Disorder, Connective Tissue Disorder, Hemophilia, Thrombosis, Von Willebrand Diseases, Thrombophilia, Rare Bleeding Disorder, Platelet Disorder, Factor IX Deficiency, Factor VIII Deficiency, Thalassemia, Sickle Cell Disease | 06/35 | 12/35 | | |
